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Abstract
Deafness, the most frequent sensory deficit in humans, is extremely heterogeneous with hundreds of genes involved. Clini-
cal and genetic analyses of an extended consanguineous family with pre-lingual, moderate-to-profound autosomal recessive 
sensorineural hearing loss, allowed us to identify CLRN2, encoding a tetraspan protein, as a new deafness gene. Homozygo-
sity mapping followed by exome sequencing identified a 14.96 Mb locus on chromosome 4p15.32p15.1 containing a likely 
pathogenic missense variant in CLRN2 (c.494C > A, NM_001079827.2) segregating with the disease. Using in vitro RNA 
splicing analysis, we show that the CLRN2 c.494C > A variant leads to two events: (1) the substitution of a highly conserved 
threonine (uncharged amino acid) to lysine (charged amino acid) at position 165, p.(Thr165Lys), and (2) aberrant splicing, 
with the retention of intron 2 resulting in a stop codon after 26 additional amino acids, p.(Gly146Lysfs*26). Expression 
studies and phenotyping of newly produced zebrafish and mouse models deficient for clarin 2 further confirm that clarin 2, 
expressed in the inner ear hair cells, is essential for normal organization and maintenance of the auditory hair bundles, and 
for hearing function. Together, our findings identify CLRN2 as a new deafness gene, which will impact future diagnosis and 
treatment for deaf patients.
Introduction
The mammalian inner ear is an exquisite and highly complex 
organ, made up of the vestibule, the organ responsible for 
balance, and the cochlea, the sensory organ for hearing. The 
auditory sensory cells of the inner ear are called the inner 
and outer hair cells that are responsible for transduction of 
sound wave-induced mechanical energy into neuronal sig-
nals (Gillespie and Müller 2009; Hudspeth 1997). The func-
tional mechanoelectrical transduction machinery involves 
intact formation and maintenance of a highly specialized 
and organized structure, the hair bundle. The hair bundle 
contains a few dozen F-actin-filled stereocilia, arranged in 
a highly interconnected and highly organized staircase-like 
pattern, which is critical for function (Kazmierczak et al. 
2007). Knowledge of the mechanisms of formation, main-
tenance, and function of the transduction complex is limited 
(Cunningham and Müller 2019). In this regard, identification 
of novel genes that encode protein products essential for 
hearing is likely to improve our understanding of the physi-
cal, morphological and molecular properties of hair cells and 
associated mechanistic processes.
Hereditary hearing loss is one of the most common and 
genetically heterogeneous disorders in humans (Wright et al. 
2018). Sensorineural hearing loss has an incidence of 1 to 
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2 per 1000 at birth (Morton and Nance 2006). It displays 
extraordinary phenotypic, genetic and allelic heterogeneity, 
with up to 1000 different genes potentially involved (Ing-
ham et al. 2019). So far, about 120 genes and more than 
6000 disease causing variants (Azaiez et al. 2018) have been 
identified as responsible for non-syndromic hearing loss in 
humans (see http://hered itary heari nglos s.org/ and http://
deafn essva riati ondat abase .org/), and many more are yet to 
be discovered. Genetic factors predominate the etiological 
spectrum and most hereditary hearing loss appears to fol-
low an autosomal recessive inheritance pattern (Smith et al. 
2005). To date, approximately 80% of the known autosomal 
recessive deafness-associated genes have been originally 
identified by studying extended consanguineous families 
(Hofrichter et al. 2018). There are many forms of hearing 
loss that are clinically indistinguishable but caused by dis-
tinct genetic entities that are presently unknown. Identifi-
cation of additional genes essential for auditory function, 
through the study of families exhibiting hereditary hearing 
loss, will not only help increase our understanding of the 
biology of hearing, but will also identify new molecular tar-
gets for therapeutic intervention.
Through the study of an extended consanguineous Ira-
nian family, we have identified a CLRN2 coding lesion as 
the likely cause of hearing loss in family members that are 
homozygous for the allele. We have established that clarin 2 
likely plays a critical role in mechanotransducing stereocilia 
of the hair bundle in zebrafish and mouse. CLRN2 belongs 
to the clarin (CLRN) family of proteins that are comprised 
of three orthologues named clarin 1, 2, and 3 that encode 
four-transmembrane domain proteins. Pathogenic variants in 
CLRN1 (clarin 1) cause either non-syndromic retinitis pig-
mentosa (RP) (Khan et al. 2011) or Usher syndrome type 3A 
(USH3A), that is characterized by progressive hearing loss, 
RP and variable vestibular dysfunction (Adato et al. 2002; 
Joensuu et al. 2001; Ness et al. 2003; Plantinga et al. 2005). 
This study establishes clarin 2 as essential for inner ear func-
tion in zebrafish, mice and humans, with a loss-of-function 
allele leading to autosomal recessive non-syndromic senso-
rineural hearing loss (ARNSHL).
Materials and methods
Patient clinical and audiometry data
Written informed consent was provided from all participat-
ing individuals. This study has been approved by the Fac-
ulty of Medicine ethics commissions at the University of 
Würzburg (46/15) and Shahid Chamran University of Ahvaz 
(#EE/97.24.3 17654). A three generation Iranian family of 
Lurs ethnicity was ascertained as part of a large ethnically 
diverse Iranian population rare disease study. Pure-tone 
audiograms and medical information were collected from 
participating members. Clinical examination excluded addi-
tional syndromic features.
Individuals IV-1, IV-6, and V-1 (Fig. 1) underwent com-
plete ear, nose and throat examination, including binocular 
ear microscopy and external ear inspection. Routine pure-
tone audiometry was performed according to current stand-
ards that measured hearing thresholds at frequencies 0.25, 
0.5, 1, 2, 4, 6 and 8 kHz. Both air- and bone-conduction 
thresholds were determined. Severity of hearing loss was 
defined as previously described (Mazzoli et al. 2003). Indi-
viduals IV-1 and IV-6 underwent additional tympanometry 
and speech recognition threshold testing. Audiometry testing 
for individuals IV-1, IV-6, and V-1 was performed at ages 
29, 44, and 20 years, respectively.
Genotyping, gene mapping, copy number variation 
and exome sequencing data analyses
Due to parental consanguinity and suspected autosomal 
recessive mode of inheritance, we assumed that the causal 
variant would be homozygous and identical by descent in 
affected individuals in the fourth generation of the family. 
Blood samples from 14 family members were obtained and 
genomic DNA was isolated from whole blood using stand-
ard procedures. DNA from affected (IV-1, IV-6, and IV-8) 
and unaffected (IV-2, IV-3, IV-4, and IV-5) individuals were 
genotyped using the Infinium Global Screening Array-24 
v1.0 BeadChip (Illumina, San Diego, CA, USA) according 
to manufacturer’s protocols. Copy number variation calling 
was performed using GenomeStudio v.2011.1 and cnvParti-
tion 3.2.0 (Illumina).
From the 618,540 markers on the array, we filtered out 
InDels, MT- and Y-chromosomal SNPs, multi-allelic SNPs, 
SNPs with missing genotypes in more than one individual, 
and SNPs having a minor allele frequency (MAF) lower 
than 5% in gnomAD European individuals (NFE) result-
ing in 242,705 bi-allelic SNPs for quality control (QC) and 
Linkage analysis. Data conversion to Linkage format files 
and QC was managed with the ALOHOMORA software 
(Rüschendorf and Nürnberg 2005). The sex of individuals 
was estimated by counting heterozygous genotypes on the 
X-chromosome and compared to the given pedigree data. 
The relationships between family members were verified 
with the program Graphical Relationship Representation 
(GRR) (Abecasis et al. 2001). PedCheck (O’Connell and 
Weeks 1998) was used to detect Mendelian errors (ME) and 
SNPs with ME were removed from the data set. Unlikely 
genotypes, e.g., double recombinants, were identified with 
Merlin (Abecasis et al. 2002) and deleted in the individuals.
Linkage analysis was performed with Merlin (Abe-
casis et al. 2002) using an autosomal recessive mode of 
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inheritance with complete penetrance and a mutant allele 
frequency of 0.001. To avoid the problem of Linkage Dise-
quilibrium (LD) between markers, which can lead to inflated 
LOD scores, we created a less dense, LD-reduced marker 
set of 91,426 SNPs with a minimal distance of 10,000 bases 
between markers and a MAF > 0.15. The exact position of 
the LOD score regions, e.g., the recombination events, were 
identified with the full marker set of 242,705 SNPs.
Additionally, homozygosity mapping was performed 
using HomozygosityMapper to identify common homozy-
gous intervals among the affected individuals (Seelow et al. 
2009). Runs of homozygosity with a maximum threshold 
of 0.99 were checked after the exome-wide analysis was 
completed.
For exome sequencing, DNA samples from two affected 
individuals (IV-1 and IV-6) were used. The data from indi-
vidual IV-6 were analyzed exome-wide and data from indi-
vidual IV-1 were used for determination of allele sharing. 
Exome capture using genomic DNA was performed using 
the SureSelect Target Enrichment v6 (Agilent) kit follow-
ing manufacturer’s recommendations. The libraries were 
sequenced with a HiSeq4000 (Illumina). Data analysis was 
performed using the Burrows–Wheeler Alignment (BWA) 
tool for read mapping to the human reference genome 
GRCh37 (hg19), Picard for duplicate removal, GATK for 
local re-alignment, base recalibration, variant calling, and 
variant annotation, and SnpEff for variant annotation. Vari-
ant filtering was based on: coverage > 10X, Phred quality 
score ≥ 30, and MAF ≤ 0.005 as reported in 1000 Genomes 
Project and EVS6500. Variants were filtered based on cod-
ing effect (non-synonymous, synonymous, indels, and splice 
site variants), and artifact-prone genes (HLAs, MAGEs, 
MUCs, NBPFs, ORs, PRAMEs) were excluded. ACMG 
guidelines were used for variant interpretation (Oza et al. 
2018). Visualization was performed using the Integrative 
Genomics Viewer. Analysis of homozygous and compound 
heterozygous variants between the two sequenced affected 
individuals (IV-6 and IV-1) followed. We analyzed missense 
Fig. 1  Pedigree, audiological data, genetic data, and locus mapping. 
a The consanguineous family of Iranian origin with hearing loss and 
segregation of the CLRN2 c.494C > A variant. Linked haplotypes har-
bouring the pathogenic variant coloured in red with meiotic recom-
bination SNP markers underlined. SNP positions are annotated using 
the GRCh37 human genome assembly. b Pure-tone audiograms from 
affected individuals IV-1 (red) and IV-6 (blue), as well as an unaf-
fected heterozygous individual V-1 (green). Air-conduction thresh-
olds in dB HL for the right and left ears are represented by circles 
and crosses, respectively. Bone-conduction thresholds are represented 
by < and > for right and left ears, respectively, and confirm a senso-
rineural hearing loss in the affected individuals. c Linkage mapping 
reveals a 14.96  Mb locus on chromosome 4 containing CLRN2. d 
Sequence electropherograms showing the homozygous, heterozygous 
and WT images of the CLRN2 c.494C > A; pThr165Lys pathogenic 
variants
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variants using a combination of criteria that scored conser-
vation using GERP++ and PhyloP, and deleterious or path-
ogenic scores in Combined Annotation Dependent Deple-
tion (CADD) (Kircher et al. 2014), LRT (Chun and Fay 
2009), MutationTaster (Schwarz et al. 2014), PolyPhen-2 
(Adzhubei et al. 2010), and SIFT (Ng and Henikoff 2001). 
Missense variants were excluded when three out of five in 
silico pathogenicity prediction tools yielded a benign score. 
Manual MAF analysis used gnomAD (Lek et al. 2016), 
GME (Scott et al. 2016) and Iranome (Fattahi et al. 2019). 
Potential effects on splicing were assessed using ESEfinder 
(Cartegni et al. 2003) and RESCUE-ESE (Fairbrother et al. 
2004).
Segregation, sequence and in vitro splicing analyses 
of the CLRN2 c.494C > A likely pathogenic variant
To confirm segregation of the CLRN2 c.494C > A; 
p.(Thr165Lys) (NM_001079827.2) homozygous variant, 
Sanger sequencing was completed in all 14 family members 
using the following primers (CLRN2 Ex3 F: 5′-AAA TGC 
CAC CTC TTA CAG AGT TGC -3′ and CLRN2 Ex3 R: 5′-ACC 
GTG GCC TCT TCG ATT TTG GTC -3′) and standard PCR and 
sequencing parameters.
To document residue conservation, CLRN1 (UniProt: 
P58418) and CLRN2 (UniProt: A0PK11) were aligned and 
visualized in Jalview (Waterhouse et al. 2009) with an over-
view of the pathogenic and likely pathogenic missense and 
nonsense CLRN1 variants retrieved from the Deafness Vari-
ation Database v 8.2 (Azaiez et al. 2018).
In addition, secondary protein structure prediction of 
human CLRN2 (NP_001073296.1) that included the wild-
type (WT) and mutated amino acid residues was performed 
using I-TASSER (Yang et al. 2015).
To assess the splicing effect of the c.494C > A variant, 
in vitro splicing assays, also called mini-genes, were car-
ried out as described (Booth et al. 2018a, b). WT CLRN2 
exon 3 (266 bp) plus 183 and 51 nucleotides from intron 
2 and the 3′UTR were PCR amplified with gene-specific 
primers containing Sall or SacII restriction enzyme sites, 
respectively. After PCR amplification, clean up, and restric-
tion enzyme digestion, the PCR fragment was ligated into 
the pET01 Exontrap vector (MoBiTec) and the sequence 
was confirmed. Variants were then introduced into the 
WT sequence using QuikChange Lightning Site-Directed 
Mutagenesis (Agilent) according to the manufacturer’s pro-
tocols via overlapping primers containing the alteration. The 
WT and mutant mini-genes were sequence confirmed.
WT or mutant mini-genes were transfected in triplicates 
into COS-7 and ARPE-19 cells using TransIT-LT1 Trans-
fection Reagent (Mirus). Cells were harvested 36 h after 
transfection and total RNA was extracted using Quick-RNA 
MiniPrep Plus kit (ZYMO Research). cDNA was transcribed 
using 750 ng of isolated RNA SuperScript™ III Reverse 
Transcriptase (ThermoFisher Scientific) using a primer spe-
cific to the 3′ native exon of the pET01 vector according to 
manufacturer’s protocol. PCR amplification followed using 
primers specific to the 5′ and 3′ native exons of the pET01 
vector, and products were visualized on a 1.5% agarose gel. 
As a negative control, rs117875715 (chr4(GRCh37):g.17,5
28,480G > A), a benign polymorphism, was used to test and 
validate the designed mini-gene assay.
Concurrently, the mini-gene splice assay experiment 
was conducted in a double-blind manner as previously 
described (Lekszas et  al. 2020). Genomic DNAs of an 
affected homozygous (IV-6) and WT individual (IV-5) were 
amplified using a forward primer with a XhoI restriction site 
(CLRN2 Ex3 XhoI F: 5′-aattctcgagTTG CAG TGA GCT GAG 
ATG GT-3′) and a reverse primer with a BamHI restriction 
site (CLRN2 Ex3 BamHI R: 5′-attggatccGCC TTG CGA AGT 
TGT TAC TG-3′). The 886 bp amplicon included the entire 
exon 3 sequence plus additional flanking 320 bp (5′) and 
306 bp (3′) sequence that was ligated into a multiple cloning 
site between native exons A and B in the linearized pSPL3b 
exon-trapping vector. The vector was transformed into DH5α 
competent cells and plated overnight. All mutant mini-genes 
were Sanger sequence confirmed.
Homozygous and WT mini-genes were transfected in 
triplicate into HEK 293 T cells cultured in FCS-free medium 
in 6 well culture plates with a density of 2 × 105 cells per 
mL. The mini-genes in the pSPL3b vector were transiently 
transfected using 6 µl of FuGENE 6 Transfection Reagent 
(Roche) with 2 µg of vector. An empty vector and HEK 
293 T cells were included as controls. The transfected cells 
were harvested 24–48 h post-transfection. Total RNA was 
prepared using the miRNAeasy Mini Kit (Qiagen). Approxi-
mately, 1 µg of RNA was reverse transcribed using a High 
Capacity RNA-to-cDNA Kit (Applied Biosystems) follow-
ing manufacturer’s protocols. The cDNA was used for PCR 
amplification using a vector specific SD6 forward (5′-TCT 
GAG TCA CCT GGA CAA CC-3′) and a terminal CLRN2 exon 
3 reverse cDNA primer (5′-CAA GAT ATC CTC AGC TGT 
GACC-3′). The resulting amplified fragments were visual-
ized on a 1.5% agarose gel. cDNA amplicons were Sanger 
sequenced. cDNA amplicons from the homozygous indi-
vidual were cloned following standard protocols for the TA 
cloning (dual promoter with pCRII) kit (Invitrogen).
CRISPR/Cas9‑mediated inactivation of clrn2 
in zebrafish
Zebrafish (Danio rerio) were raised and maintained in 
an AALAC accredited facility at the Oklahoma Medical 
Research Foundation (OMRF) under standard conditions. 
Zebrafish embryos/larvae were maintained in embryo 
medium with 0.00002% methylene blue and raised at 28 °C. 
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All animal experiments were performed as per protocol (17-
01) and approved by the Institutional Animal Care Commit-
tee of OMRF (IACUC). All zebrafish handling, embryo care, 
and microinjections were performed as previously described 
(Westerfield 2000). WT zebrafish strain NHGRI-1 was 
used for all experiments (LaFave et al. 2014). The zebrafish 
embryonic staging was determined by morphological fea-
tures according to (Kimmel et al. 1995).
To produce zebrafish clrn2 crispants, the sgRNA target 
sequences were selected from the UCSC genome browser 
tracks generated by the Burgess lab. Five independent targets 
were chosen and sgRNAs were synthesized by in vitro tran-
scription as described earlier (Varshney et al. 2016). sgR-
NAs and Cas9 protein complex were used to generate indels. 
A 6 µL mixture containing 2 µL of 40 µM Spy Cas9 NLS 
protein (New England Biolabs, MA, USA), 200 ng each of 
five sgRNAs (in 2 µL) and 2 µL of 1 M potassium chloride 
was injected into one-cell-stage WT embryos. Injection 
volumes were calibrated to 1.4 nL per injection. Insertion/
deletion (indel) variants were detected by amplifying the 
target region by PCR and Sanger sequencing as described 
earlier (Varshney et al. 2016). The sequencing data were 
analyzed by Inference of CRISPR Edits (ICE) v2 CRISPR 
analysis tool. The sgRNA target sequences and PCR primer 
sequences are listed in Supplementary Table S1.
Zebrafish RNA extraction and quantitative reverse 
transcription PCR (RT‑qPCR)
Total RNA at different developmental stages, adult tissues, 
and CRISPR/Cas9 injected larvae were extracted using 
the TRIzol Reagent (Thermo Fisher Scientific, CA, USA) 
and purified by RNA clean and concentrator-5 kit (Zymo 
Research, CA, USA) according to the manufacturer’s 
instructions. RNA concentration was measured by DeNovix 
DS-11 spectrophotometer (DeNovix Inc., USA). The cDNA 
was synthesized by iScript RT Supermix (Bio-Rad, USA), 
and was used as a template for performing the RT-qPCR 
with SYBR Green Supermix (Thermo Fisher Scientific, CA, 
USA) and the Light Cycler® 96 System (Roche, CA, USA). 
All RT-qPCR reactions were carried out using three biologi-
cal and technical replicates. The housekeeping gene 18S was 
used as a reference gene.
All RT-qPCR primer pairs were designed across exon-
exon junctions using NCBI Primer-BLAST program (Sup-
plementary Table S1). PCR cycling conditions were used as 
per manufacturer instructions. All reactions were carried out 
using three biological and technical replicates. The house-
keeping gene 18S was used as a reference gene. Amplifica-
tion specificity was assessed by dissociation curve analysis. 
The cycle threshold values (Ct) data were imported into 
Microsoft Excel for the relative gene expression analysis. 
Quantification was based on 2^(−ΔΔCT) method (Livak and 
Schmittgen 2001), and using 18 h post fertilization (hpf) for 
clarin 2 temporal expression, muscle for clarin 2 in differ-
ent tissue expression and the corresponding age-matched 
control for clarin 2 CRISPR injected  F0 larvae as normali-
zation control.
Distribution of clrn2, phalloidin staining 
and behavioral analysis in zebrafish
To determine clrn2 expression, we used in situ hybridi-
zation on larvae and inner ear-containing cryosections. 
The full-length coding sequence of zebrafish clarin 2 
(NM_001114690.1) was PCR amplified from WT zebrafish 
cDNA using primer pairs with BamHI and XhoI restriction 
sites cloned into the pCS2+ vector (a kind gift from Dr. Dave 
Turner, University of Michigan). After restriction digestion, 
the resulting clones were sequenced and used as templates 
for riboprobe synthesis. The digoxigenin-UTP-labeled ribo-
probes were synthesized according to the manufacturer’s 
instructions (Millipore Sigma, MO, USA). Briefly, the clarin 
2 and the pvalb9 plasmids (Horizon Discovery) were line-
arized by BamHI and NotI restriction enzymes, respectively. 
The linearized plasmid was purified and used as template 
for in vitro transcription using T7 RNA polymerase to syn-
thesize anti-sense probes. The sense probe was made using 
XbaI linearized clarin 2 plasmid and SP6 RNA polymerase.
Whole-mount in situ hybridization (WISH) on 3 and 5 
dpf zebrafish embryos/larvae was performed following the 
procedures as described by Thisse et al. with minor modi-
fications (Thisse and Thisse 2008). Age-matched zebrafish 
embryos were randomly collected by breeding WT zebrafish 
pairs. The embryos were treated with 0.003% phenylthiourea 
(PTU) (Millipore Sigma, MO, USA) in embryo medium at 
1 day post-fertilization (dpf) until the desired stages reached 
to reduce the pigment formation that will facilitate color 
visualization during in situ hybridization. Embryos/larvae 
were then fixed with 4% (V/V) paraformaldehyde in phos-
phate-buffered saline (PBS) at 3 and 5 dpf. An additional 
bleaching step was carried out after fixation by incubating 
the embryos at room temperature in a 3% hydrogen peroxide 
and 0.5% potassium hydroxide solution. The permeabiliza-
tion of 3 dpf embryos and 5 dpf larvae was performed using 
2 µg/mL proteinase K for 12 and 18 min, respectively. Color 
development was conducted using the BM-Purple alkaline 
phosphatase substrate (Millipore Sigma, MO, USA).
For preparation of cryo-sectioned samples after WISH, 
the 5 dpf larvae were soaked in 25, 30% (V/V) sucrose/PBS 
and optimum cutting temperature (OCT) each for at least 
2 days, and embedded in OCT, then Cryotome sectioned at 
a 10-µm thickness.
For phalloidin staining of the zebrafish inner ear, 5 dpf 
larvae were euthanized with tricaine and fixed in 4% (V/V) 
paraformaldehyde (PFA) at 5 dpf, fixed embryos were 
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washed by PBSTx (1% PBS, 0.2% triton X-100) and incu-
bated in 2% triton X-100 in PBS at room temperature for 
overnight with agitation until the otoliths were completely 
dissolved. The larvae were sequentially washed in PBSTx 
and incubated with Alexa Fluor 488 Phalloidin (1:50) 
(Thermo Fisher Scientific, CA, USA) in PBSTw (1% PBS, 
0.1% Tween-20) at room temperature for 4 h. The samples 
were washed in PBSTx after staining and mounted laterally 
in 75% glycerol on slides. Images were acquired with a Zeiss 
LSM-710 Confocal microscope.
To perform the acoustic evoked behavioral response 
(AEBR) test, 6 dpf larvae were placed in a 48-well plate 
with 200 µL embryo water and placed in a Zebrabox (View-
Point Life Sciences) and embryos were adapted in the dark 
for 15–30 min (until spontaneous movements were less fre-
quent). The embryos were subjected to a 100 ms, 1 kHz pure 
tone at 100% target power every 20 s for 4 min (12 stimuli) in 
the dark. The Zebrabox recorded the animals using infrared 
light and measured the activity as pixel changes over time. 
The burst threshold was set at 50 pixels, the freeze threshold 
set at 10 pixels, and sensitivity was set at 20 pixels. Move-
ment over the 50 pixel burst threshold within the 2 s after 
stimulus was considered an evoked response. Responses 
were excluded if the larvae had spontaneous movement 
within the 2 s before the stimulus. All responses for a larva 
were excluded if they had spontaneous movement before 6 
or more of the stimuli. The response rate was calculated by 
how many times an embryo had an evoked response out of 
the total number of stimuli and converted to a percentage.
Production and phenotyping of clarin 2 deficient 
mutant in mice
The Clrn2del629 mutant line was generated on a C57BL/6N 
background by the Molecular and Cellular Biology group 
at the Mary Lyon Centre (MLC), MRC Harwell Institute, 
using CRISPR/Cas9 genome editing (Dunbar et al. 2019). 
The mice were housed and maintained under specific path-
ogen-free conditions in individually ventilated cages, with 
environmental conditions as outlined in the Home Office 
Code of Practice. Animals were housed with littermates until 
weaned, and then housed with mice of the same sex and of 
similar ages, which was often their littermates. Both male 
and female animals were used for all experiments. Animal 
procedures at the MRC Harwell Institute were licenced by 
the Home Office under the Animals (Scientific Procedures) 
Act 1986, UK and additionally approved by the Institutional 
Animal Welfare and Ethical Review Body (AWERB). The 
Clrn1−/− mice (Clrn1tm1.2Ugpa, MGI: 6099052) used for com-
parative scanning electron microscopy analyses were previ-
ously described (Dulon et al. 2018).
To screen mice for auditory phenotypes and investigate 
auditory function, Auditory Brainstem Response (ABR) 
tests (measured using a click stimulus and frequency-spe-
cific tone-burst stimuli (at 8, 16 and 32 kHz) and Distortion 
Product Oto-Acoustic Emission (DPOAE) tests (measured 
using frequency-specific tone-burst stimuli from 8 to 32 kHz 
with the TDT RZ6 System 3 hardware and BioSig RZ soft-
ware (Tucker Davis Technology, Alachua, FL, USA)) were 
performed as described in Dunbar et al., 2019. For scan-
ning electron microscopy imaging, fixed inner ear samples 
were processed by the osmium tetroxide/thiocarbohydrazide 
(OTOTO) method, as previously described (Dulon et al. 
2018; Dunbar et al. 2019). Samples were visualized with 
a JSM-6010LV Scanning Electron Microscope (JEOL). 
Micrographs were pseudo-coloured in Adobe Photoshop.
Statistical analysis
To compare the clrn2 mRNA expression in zebrafish, data 
are presented as mean values ± standard deviation (SD). 
Statistical analysis was performed using GraphPad Prism 
version 8.4 (GraphPad Software, San Diego, CA, USA). The 
significance level was set to 0.05. The p value was deter-
mined using a two-tailed unpaired Student’s t-test for RT-
qPCR of clrn2 mRNA expression, and a two-tailed unpaired 
nonparametric Mann–Whitney U test for AEBR analysis. 
The statistical significance is represented in the figures as 
***p < 0.001.
To assess ABR thresholds and DPOAE responses in the 
Clrn2del629 mice, one-way ANOVA statistical tests were 
used. Each frequency was tested for statistical significance 
separately. A threshold of p > 0.05 was used to determine if 
differences were statistically significant. Statistical signifi-
cance is represented in the figure as follows: ***p < 0.001. 
All data shown are mean ± SD, and all statistical analyses 
was performed in GraphPad Prism.
Results
Identification of CLRN2 as a novel deafness gene 
in a consanguineous Iranian family exhibiting 
autosomal recessive non‑syndromic sensorineural 
hearing loss
A three generation Iranian family of Lurs ethnicity was 
ascertained as part of a large ethnically diverse Iranian pop-
ulation rare disease study (Fig. 1a). Three individuals that 
included the proband (IV-6), his sibling (IV-1), and a cousin 
(IV-8), born form consanguineous marriages, have reported 
moderate-to-profound bilateral non-syndromic sensorineu-
ral hearing loss (Fig. 1b). The age of onset for these three 
individuals was between 2 and 3 years of age. Pure-tone 
air- and bone-conduction audiometry thresholds (Fig. 1b) 
show evidence of intrafamilial variability. Individual IV-1 
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has a down sloping audiogram, with bilateral moderate-to-
profound deafness. Individual IV-6 presented a moderate-
to-severe hearing loss with slightly better hearing at higher 
frequencies. Both individuals showed normal (type A) tym-
panograms bilaterally. Speech recognition thresholds for 
individual IV-1 were 80 and 75 dB at 84 and 88% for right 
and left ears, respectively, and a most comfortable level of 
95 dB. Speech recognition thresholds for individual IV-6 
were 75 and 80 dB, each at 84%, for right and left ears, 
respectively. Patients have normal neuromotor, speech and 
language development, and did not show signs of impaired 
balance. No other abnormalities, including potential vision 
deficit, were present in the affected individuals, who were 
last evaluated at the age of 29 (IV-1), 44 (IV-6), and 25 (IV-
8) years. For comparison, pure-tone audiometry was also 
recorded from a family member (V-1), with no reported his-
tory of hearing deficits.
To identify the underlying genetic lesion, genome-wide 
linkage analysis identified one single significant maximum 
LOD score of 3.8 on chromosome 4 (Supplementary Fig. 
S1a-b). Linkage analysis and haplotyping with the dense 
marker set showed the adjacent markers rs7690593 and 
rs608053 (GRCh37/hg19, chr4: 17,298,007–32,261,222 bp, 
hg19). The homozygous region spans 14.96 Mb and over-
laps with the CLRN2 gene position (Fig. 1c). As a second 
independent method, we applied homozygosity mapping in 
the extended family to identify a 15.2 Mb locus on chro-
mosome 4p15.32p15.1 (GRCh37/hg19, chr4:17,298,445-
32,495,165), defined by the SNPs rs7692897 and 
rs17081424 (Supplementary Fig. S1c, Supplementary 
Table S2) that mirror the linkage results. This locus contains 
30 genes, none of which are presently associated with deaf-
ness in humans (Supplementary Table S2). This approach 
also revealed four much smaller homozygous intervals on 
chromosomes 2p21 (137.3 kb), 3p22.2 (262.5 kb), 13q13.1 
(90.7 kb), and 17q21.31 (292.6 kb) (Supplementary Fig. 
S1c, Supplementary Table S2) that do not contain known 
deafness-associated genes (Supplementary Table  S2). 
Pathogenic copy number variations were excluded. Next, 
we undertook exome sequencing of affected individual 
IV-6 (arrow, Fig. 1a). This generated 56,387,543 mappa-
ble reads, with 75.5% on-target reads. The mean depth was 
57.3-fold, with 97.3% of regions with a tenfold read depth. 
Analysis of the exome data of individual IV-6 excluded any 
candidate pathogenic variants in known deafness-associated 
genes (Doll et al. 2020) prompting an exome-wide analysis 
followed by filtering and re-analysis of variants in homozy-
gous intervals (Supplementary Table S3). Further, close 
inspection of the exome sequencing data revealed complete 
sequencing coverage of genes in the homozygous intervals 
(Supplementary Table S4). Variant filtering detected a sin-
gle homozygous missense variant in CLRN2 c.494C > A, 
(p.(Thr165Lys)) (NM_001079827.2) in the linked and 
homozygous interval on chromosome 4 (Supplementary 
Fig. S1a–c). This variant was shared with individual IV-1 
and segregated in the extended family comprising a total 
of 14 individuals (Fig. 1a, d) and was the only remaining 
variant in the locus fulfilling variant filtering criteria. Only 
individuals homozygous for the CLRN2 c.494C > A variant 
exhibit hearing loss confirming the recessive nature of the 
allele (Fig. 1a). This variant fulfills ACMG criteria for clas-
sification as likely pathogenic (PM2_Moderate, PP1_Strong, 
PP3_Supporting).
The CLRN2 c.494C > A leads to a likely pathogenic 
missense substitution and aberrant splicing
The c.494C > A variant on chromosome 4p15.32 is unani-
mously predicted to be deleterious and disease causing by 
in silico tools (Supplementary Table S5). The c.494C > A 
variant in CLRN2 replaces a polar uncharged amino acid 
(threonine) with a positively charged amino acid (lysine) in 
clarin 2, (p.(Thr165Lys)) (Creixell et al. 2012). This variant, 
as well as homozygous loss-of-function alleles, are absent 
in population frequency databases. This suggests CLRN2 
is intolerant to biallelic loss-of-function. Our in-house col-
lection of 89,041 additional exomes/genomes, including a 
multiethnic cohort of 842 exomes from probands with auto-
somal recessive hearing loss, identified four individuals from 
three families of Iranian, Turkish, and Emirati ethnicities, 
who carried the CLRN2 c.494C > A variant (allele frequency 
2.24 × 10–5). An Iranian hearing impaired individual was 
included among the carriers.
The c.494C > A variant involves the exchange of a 
novel polar threonine (Thr) residue to a basic lysine (Lys) 
amino acid that affects a highly conserved amino acid in 
the alpha-helix of the PMP-22/EMP/MP20/Claudin super-
family domain (Fig. 2a–c). Among clarin proteins, clarin 
2 and clarin 1 show 34.9% identity with 81 identical and 
91 similar amino acids (using UniProt (UniProt Consor-
tium 2018), Fig. 2b). The outcome of CLRN1 pathogenic 
or likely pathogenic missense variants, as well as nonsense 
variants (queried from the Deafness Variation Database v8.2 
(Azaiez et al. 2018)) are marked in red (Fig. 2b) along with 
the clarin 2 p.(Thr165Lys) amino acid substitution (Fig. 2b, 
asterisk). Interestingly, nine out of the 19 clarin 1 amino 
acid mutated residues are identical in clarin 2. Three clarin 
1 amino acid substitutions (p.(Leu163Pro), p.(Leu167Trp), 
and p.(Ile181Asn), NP_001182723.1) align in close prox-
imity to the clarin 2 p.(Thr165Lys). Furthermore, clarin 1 
p.Leu163Pro (Fields et al. 2002) and p.Ile181Asn (García-
García et al. 2012), that are both reported in USH3A, are 
p.Leu150 and p.Ile168 in clarin 2. Most importantly, the 
threonine residue at position 165 (Thr165) CLRN2 is con-
served across species and the corresponding amino acid 
in clarin 1 is a serine residue (Fig. 2a-b), a scenario often 
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associated with conserved phosphorylation site residue, here 
by serine/threonine protein kinases (Creixell et al. 2012).
In addition to causing an amino acid missense sub-
stitution, computational analysis also predicts that the 
c.494C > A variant will create an exonic splicing enhancer 
(ESE) motif, modifying the ESE hexameric sequence land-
scape of exon 3, which could interfere with the normal pro-
cessing of CLRN2 mRNA (Figs. S2a–b; ESEfinder and RES-
CUE-ESE, Human Splicing Finder) (Cartegni et al. 2003; 
Desmet et al. 2009; Fairbrother et al. 2004). To investigate 
Fig. 2  Conservation of the p.Thr165 residue, and clarin 1/clarin 2 
alignment. a Overview of clarin 2 protein and modular structure of 
the PMP-22/EMP/EP20/Claudin superfamily, with amino acid resi-
due coordinates and position of the p.(Thr165Lys) substitution shown 
(upper panel). An alignment of the amino acid sequences from the 
segment of clarin 2 (represented by dashed lines) from vertebrate 
species shows the Thr165 position (asterisk) is well conserved 
among vertebrates. b Alignment of clarin 2 (UniProtKB: A0PK11, 
upper alignment) and clarin 1 (UniProtKB: P58418, lower align-
ment) amino acid residues. Transmembrane domains are marked in 
grey, conservation is shown in yellow, and consensus sequences are 
shown below for the 232 amino acid proteins. Missense and nonsense 
variants in clarin 1 (Deafness Variation Database v8.2) and clarin 2 
(present study, asterisk) are marked in red. c The predicted secondary 
structure of human clarin 2 (NP_001073296.1) wild-type (Thr165) 
and mutated (Thr165Lys) protein. H represents alpha-helix, S repre-
sents beta-strand and C represents coil
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the effect of the c.494C > A variant on CLRN2 splicing, we 
used mini-gene assays using two different exon-trapping vec-
tors and three different cell lines, Cos-7, ARPE-19, and HEK 
293 T. The mini-gene contained the 3′ end of intron 2, all of 
exon 3 (with and without the CLRN2 variant), and ~ 50 bp 
of the 3′ UTR (Fig. 3a) and was transfected into COS-7 and 
ARPE-19 cells. As a negative CLRN2 control, we used the 
rs117875715 SNP, a common polymorphism, with a global 
MAF of ~ 1.25% and > 100 homozygous alleles reported in 
gnomAD (Lek et al. 2016) (http://gnoma d.broad insti tute.org/
varia nt/4-17528 480-G-A) that is 20 nucleotides away from 
c.494C > A. Given its frequency, rs117875715 is predicted 
to be benign for hearing loss. Of note, this polymorphism 
is absent in the proband and family members reported here. 
Since exon 3 is the last exon of CLRN2, we designed our 
PCR primers to exclude the human poly-A signal and used 
the poly-A signal native to the pET01 vector. As expected 
for WT CLRN2 (c.494C), we detected the splicing of the 5′ 
Fig. 3  Analysis of the CLRN2 c.494C > A variant on splicing. a Sche-
matic illustration of the mini-gene splice construct design. Genomic 
representation of CLRN2, including the position of the missense 
variant c.494C > A (arrow) on exon 3 with 3′ UTR (green), and the 
5′ UTR, as well as exons 1 and 2 (grey) (upper panel). Regions cap-
tured by mini-gene PCR primers are represented in brown. Schematic 
illustration of the mini-gene splice construct including exon 3 and 
its flanking sequence (green) cloned into multiple cloning sites (SalI 
and SacII sites) of pET01 backbone vector (lower panel). Blue boxes 
represent native exons of the pET01 vector. b RT-PCR of transcripts 
from post-mini-gene transfected COS-7 cells. Amplicons derived 
from the transcripts of WT (CLRN2), a benign CLRN2 polymor-
phism (rs117875715, chr4(GRCh37):g.17,528,480G > A), the CLRN2 
c.494C > A variant and a negative control, were visualized on a 1.5% 
agarose gel. The SNP, rs117875715, was used to test and validate the 
designed WT and mutant mini-gene assay. The ~ 650  bp amplicon 
was associated with the WT and validation control rs117875715. The 
amplicon derived from the CLRN2 c.494C > A transcripts showed 
two bands: a 650  bp band and a larger ~ 1360  bp band, indicat-
ing retention of intron separating the donor site of the 5′ exon and 
the acceptor site of CLRN2 exon 3. c Retention of intron in CLRN2 
c.494C > A mini-gene results in a stop codon (TGA) after CLRN2 
exon 2
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native pET01 exon only to exon 3 of CLRN2 (Fig. 3a–b). The 
same normal splicing was obtained in all cell types trans-
fected with CLRN2 containing the control (rs117875715) 
variant (Fig. 3b). However, the c.494C > A variant yielded 
two bands; one ~ 650 bp band matching the expected nor-
mally spliced exon, and a second abnormal band that was 
approximately ~ 1360 bp (Fig. 3b). Sequencing of these 
amplicons validated normal splicing including the c.494A 
variant and also revealed a retained intron 2 in the aberrantly 
spliced transcript (Supplementary Fig. S3c). The retention 
of intron 2 results in a new reading frame that introduces a 
stop codon 26 amino acids after the native exon 2 splice site 
(p.(Gly146Lysfs*26)) (Fig. 3c). These results were repli-
cated using the pSPL3b vector and HEK 293 T cells (Sup-
plementary Fig. S3a–c), confirming the c.494C > A induced 
normal and aberrant splicing, independent of the cell type 
context. Following TA-cloning of cDNA amplicons from the 
homozygous individual (from Supplementary Fig. S3b), 23 
of 26 amplicons (88.5%) showed normal splicing, and 3 of 
26 amplicons (11.5%) showed a retained intron.
The mini-gene splicing assays and sequence analyses 
clearly show that the c.494C > A affects a highly conserved 
and key residue in clarin 2 sequence, while also creating 
aberrant mRNA splicing in vivo likely leading to a trun-
cated protein. Altogether, this further confirms that variants 
in CLRN2 can lead to sensorineural hearing loss.
Clrn2, a hair cell expressed gene key to hearing 
also in zebrafish and mice
To further study the role of clarin 2 in the inner ear, we 
investigated its expression and analyzed potential impact of 
Clrn2 loss-of-function in two other species, zebrafish and 
mice.
clrn2 in zebrafish
Taking advantage of larva transparency, we used zebrafish 
as a model to investigate the clarin 2 expression during early 
embryonic development. The RT-qPCR at different develop-
mental stages revealed that clrn2 mRNA was first detected at 
18 hpf (Fig. 4a), a stage when the otic placode begins to form 
the otic vesicle in zebrafish (this stage is similar to mouse 
embryonic day 9 (E9), a stage of otic placode formation) 
(Kopecky et al. 2012; Whitfield et al. 2002). clrn2 mRNA 
expression increased (twofold at 72 and 96 hpf compared 
to 18 hpf) and was maintained at later stages, up to 120 hpf 
(Fig. 4a). Comparative analyses of clrn2 mRNA expression 
in different adult tissues of zebrafish revealed a significant 
enrichment in utricle, saccule and lagena of the inner ear 
(Fig. 4b). Our data are in agreement with RNA expression 
data from the Genotype-Tissue Expression (GTEx) project, 
wherein CLRN2 mRNA in humans is enriched in the nervous 
system, testis, kidney, salivary gland, and lung. CLRN1 has 
a similar expression profile in humans.
To determine clrn2 cellular expression, we used WISH 
in the inner ear of 3 and 5 dpf embryos (Fig. 4c–d). Unlike 
the clrn2 sense probe, the anti-sense clrn2 revealed strong 
expression in the otic vesicle, similar to the expression of 
anti-sense pvalb9, used as a marker of hair cells (Fig. 4c). 
Histological examination of 5 dpf embryos further con-
firmed that clrn2 expression is more specifically, restricted 
to hair cells, and is not expressed in the supporting cells of 
the inner ear (Fig. 4d).
To elucidate the function of clrn2 in zebrafish, we used 
CRISPR/Cas9 to generate loss-of-function alleles. To maxi-
mize the knockout efficiency, we used five sgRNAs targeting 
the first and second exon of clrn2 gene (Supplementary Fig. 
S4). Injected embryos (crispants) were sequenced and, as 
expected, a mix of alleles in the form of deletions ranging 
from 4 to 73 bp, as well as insertions spanning + 1 to + 11 bp 
were observed. The majority of the variants were frameshift 
that would most likely create a premature stop codon in the 
protein (Supplementary Fig. S4). The RT-qPCR analyses on 
injected embryos showed that clrn2 crispants have a signifi-
cantly reduced amount of clrn2 mRNA (Fig. 4e), suggest-
ing nonsense mediated decay, leading to disrupted clarin 2 
protein function.
To test acoustic responses, we performed the AEBR 
analysis. The clrn2 crispants showed significantly reduced 
response after sound stimulation (Fig. 4f) compared to the 
control animals, indicating a hearing loss phenotype. Con-
sidering clrn2 expression in hair cells (Fig. 4d), we investi-
gated the architecture of their mechanosensory hair cell bun-
dles, which are important for hearing and balance function 
in zebrafish. Interestingly, fluorescent phalloidin staining of 
the hair bundles of the inner ear in clrn2 crispants (n = 10) 
showed disrupted hair bundle structure and fewer hair cells 
compared to the WT controls (arrowheads in Fig. 4g). This 
defective phenotype, suggesting a critical role in hair bundle 
structures, is similar to the hair bundles in zebrafish clrn1 
knockouts (Gopal et al. 2015), the orbiter mutants (defec-
tive in protocadherin 15 (pcdh15), a gene associated with 
human Usher syndrome 1F) (Seiler et al. 2005) and ush1c 
morphants and ush1c mutants (Phillips et al. 2011).
Clrn2 in mice
To further assess the requirement of clarin 2 for auditory 
function in mammals, and assess further its role in auditory 
hair bundles, we extended our analyses to mouse. Consist-
ent with expression data in zebrafish (Fig. 4a, c–d), sin-
gle cell RNA-seq data available to visualize on the gEAR 
portal (umgear.org) show that in the mouse cochlear epi-
thelium at postnatal day 1 (P1) and P7, Clrn2 transcripts 
are almost exclusively detectable only in inner and outer 
925Human Genetics (2021) 140:915–931 
1 3
Fig. 4  Clarin 2 is required for the inner ear function in zebrafish. a 
RT-qPCR of clrn2 mRNA expression from 1 to 120 hpf of WT 
embryos/larvae. clarin 2 mRNA expression can be detected starting 
from 18 hpf and then increased throughout development. Data shown 
are mean ± SD and compared to 18 hpf. b RT-qPCR of clrn2 mRNA 
expression in different adult tissues. Data shown are mean ± SD and 
compared to muscle. c–d Whole-mount in situ hybridization (WISH) 
using antisense clrn2 probe reveals the inner ear expression of clrn2 
mRNA (relative dark purple color, black arrowhead) at 3 (c) and 5 
(d) dpf embryos. Sense clrn2 probe was used as negative control 
and relative light purple color is considered as background. clrn2 
mRNA was consistently expressed in hair cells within inner ear mac-
ula (c–d) with lined and arrayed structure. A known hair cell marker 
pvalb9 was used as an indicator for hair cells in the inner ear of 3 
dpf embryos (c). Cryosection was performed after clrn2 WISH at 5 
dpf to confirm the small patch of signal on the macula is from hair 
cells rather than supporting cells (d, black arrow lower panel). Scale 
bar = 100 µm, except lower panel in D (20 µm). e RT-qPCR of clrn2 
mRNA expression level was decreased 70% in clrn2 crispants com-
pared to uninjected larvae, indicating clrn2 was successfully knocked 
out (p = 2.06E-06). Data shown are mean ± SD. ***p < 0.001, two-
tailed unpaired Student’s t test. f Acoustically evoked behavioral 
responses (AEBR) in clrn2 wild type and crispants reveal significant 
reduction of sound induced responses. g Phalloidin staining on clrn2 
crispants show that the hair cells in the inner ear anterior and poste-
rior maculae display splayed, thin and split structures (purple arrow-
heads). A, anterior to the left. D, dorsal to the top. V, ventral to the 
top. Scale bar = 10 µm
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hair cell populations (Kolla et al. 2020) (see also Supple-
mentary Fig. S5). We utilized a CRISPR/Cas9-engineered 
Clrn2 mouse mutant, in which exon 2 has been deleted 
(Clrn2del629) (Fig.  5a). While this deletion leaves exon 
3 in-frame with exon 1, exon 2 encodes two of the trans-
membrane domains present in the tetraspan clarin 2 protein 
(lower panels Fig. 5a), and is therefore expected to severely 
affect protein function. In a preliminary work focused on 
clarinet mice, which display a nonsense Clrn2 mutation, 
p.(Trp4*), we showed that addition of the Clrn2del629 allele 
into the clarinet background, Clrn2clarinet/del629, was unable to 
complement the clarinet allele causing hearing loss in these 
mice, indicating Clrn2del629 is also a loss-of-function allele 
(Dunbar et al. 2019). Here, we provide the first morpho-
functional characterization of Clrn2del629/del629 mice, which, 
unlike the previously reported clarinet mice, are congenic 
on the C57BL/6N background, and measured ABRs in P21 
(± 1 day) mice in response to click and tone-burst stimuli.
Analysis of ABR thresholds, which is the lowest sound 
stimulus required to elicit measurable activity in the auditory 
Fig. 5  Clarin 2 is required for hearing function in mouse. a The genomic 
structure of mouse Clrn2 (ENSMUST00000053250), and domains of the 
encoded tetraspan-like glycoprotein (232 amino acids). The positions of 
the transmembrane (TM) domains (dark green) and the structures of the 
WT Clrn2 and Clrn2del629 alleles are indicated. Deletion of exon 2 leads 
to a shortened clarin 2 lacking the two central transmembrane domains. 
b ABR threshold measurements at P21 (± 1  day) show that Clrn-
2del629/del629 mice (red) exhibit a severe-to-profound hearing loss affect-
ing all frequencies tested, with thresholds at 80  dB SPL and beyond. 
Age-matched Clrn2+/+ (black) and Clrn2del629/+ (grey) controls display 
thresholds within the expected range (15–40 dB SPL). Averaged DPOAE 
responses at P28 (± 1 day), showing significantly reduced responses in 
Clrn2 del629/del629 mice. Data shown are mean ± SD. **p < 0.001, one-
way ANOVA. c Pseudo-colored scanning electron micrographs illustrate 
the three full rows, tallest (red), middle (blue) and short (yellow), of P28 
(± 1  day) stereocilia in IHC and OHC hair bundles. Unlike the frag-
mented hair bundle in Clrn1−/− mice, lack of clarin 2 does not affect the 
shape of IHC or OHC hair bundles. However, all the short row stereocilia 
have completely or partially regressed in the absence of either clarin pro-
tein. Scale bar = 1 µm
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nerve, showed that homozygous (Clrn2del629/del629) mice dis-
play very elevated thresholds (> 80 decibel sound pressure 
level (dB SPL)) at all frequencies tested: 8, 16 and 32 kHz 
(Fig.  5b). Whereas, Clrn2del629/+ mice exhibit thresh-
olds comparable with those of WT (Clrn2+/+) littermates 
(< 40 dB SPL), demonstrating the absence of a heterozygous 
auditory phenotype (Fig. 5b).
To further assess cochlear function, DPOAEs were meas-
ured in P28 (± 1 day) Clrn2del629/del629 mice. Compared to 
their Clrn2+/+ and Clrn2del629/+ littermates, Clrn2del629/del629 
mice have reduced DPOAEs (Fig. 5b) suggesting impaired 
outer hair cell (OHC) function.
To investigate stereocilia bundle morphology in 
Clrn2del629/del629 mice, we used scanning electron micros-
copy to examine the cochlear sensory epithelia. At P28 
(± 1 day), the inner and outer hair cell stereocilia bundles 
of Clrn2 mutant mice display the expected U- and V-shape, 
respectively, which contrasts with the grossly misshapen 
OHC bundles found in Clrn1 mutant mice (Fig. 5c). How-
ever, while the patterning of the bundles appears normal in 
Clrn2del629/del629 mice the heights of their middle and short 
row stereocilia are visibly more variable compared with 
those of Clrn2+/+ littermates, and many of the short row 
‘mechanotransducing’ stereocilia are missing (Fig. 5c).
Together, our findings establish that clarin 2 is key to 
hearing function in zebrafish and mouse, supporting that 
this protein has an evolutionary conserved role in the main-
tenance of hair bundle architecture in fish and mammals.
Discussion
We identify CLRN2 as a novel deafness gene in human and 
zebrafish and describe a new deafness-causing allele in mice. 
Genetic study using gene mapping and exome sequencing 
of an extended Iranian family with multiple consanguine-
ous marriages identified a pathogenic variant, c.494C > A 
in exon 2 of CLRN2 segregating with pre-lingual ARNSHL. 
Due to restricted expression of CLRN2 in accessible tissues 
such as blood or saliva, we performed in vitro splice analy-
sis. The c.494C > A variant results in a missense and splicing 
defect in clarin 2. By producing mutant zebrafish and mice 
lacking clarin 2, we demonstrated the key role the protein 
plays to ensure normal structural and functional integrity of 
the hair bundle, the sound- and motion-receptive structure 
of inner ear hair cells.
The clarin gene family also includes the CLRN1 gene. 
Pathogenic variants in CLRN1 have been linked to variable 
clinical outcomes, ranging from non-syndromic RP (Khan 
et al. 2011) to USH3A characterized by variable and pro-
gressive post-lingual hearing loss, RP, and variable vestibu-
lar responses (Plantinga et al. 2005). Several cases of later 
onset HL and/or RP, as late as the sixth decade of life, have 
been reported for USH3A patients (Ness et al. 2003). Clinical 
examination of affected individuals in this family, at the age 
of 25 (IV-8), 29 (IV-1), and 44 (IV-6) years of age, excluded 
the presence of additional syndromic features showing that 
homozygosity for the c.494C > A variant causes non-syndro-
mic hearing loss, ranging from moderate-severe (IV-6) to pro-
found (IV-1) deafness. In regard to the observed progressiv-
ity of the hearing impairment in clarinet mice (Dunbar et al. 
2019), the earliest reported clinical diagnosis of hearing loss 
of the CLRN2 affected individuals in the family we present 
is between 2 and 3 years of age. Newborn hearing screening 
was not routinely performed when the affected individuals 
were born, so we cannot confirm hearing was normal at birth. 
In light of absent serial audiograms, we cannot report if the 
hearing loss experienced in these patients is progressive, as 
is observed in the mouse model (Dunbar et al. 2019). So far, 
we could not identify, through our current network, additional 
families with CLRN2 variants. Featuring CLRN2 as a new 
human deafness gene, future genetic screenings of hearing 
impaired families worldwide will probably unveil additional 
CLRN2 families and provide important clues about associated 
clinical phenotype progression and severity.
Our data showed that the CLRN2 c.494C > A variant 
probably affects protein function in two ways: (1) as a mis-
sense variant (p.(Thr165Lys)) producing a mutant full length 
protein and (2) as a splice variant leading to intron reten-
tion (Fig. 3b, and Supplementary Fig. S3b–c) expected to 
cause a premature stop codon 26 amino acids into intron 2 
(p.(Gly146Lysfs*26)).
In normally spliced CLRN2 transcripts, the c.494C > A 
variant affects an amino acid that is highly conserved 
among PMP-22/EMP/EP20/Claudin superfamily proteins. 
Two potential mechanisms could synergistically contribute 
to the disruptive effect of the missense variant. First, the 
replacement of threonine with lysine, an amino acid with 
a positively charged ‘bulky’ side chain (lysine), may affect 
protein folding (Creixell et al. 2012) and transport to the 
plasma membrane. Membrane proteins sort to the plasma 
membrane via the conventional secretory pathway associ-
ated with ER-to-Golgi complex (Viotti 2016). Misfolded 
membrane proteins are typically retained in the endoplasmic 
reticulum (ER) and degraded by the ER-associated degra-
dation pathway (Kincaid and Cooper 2007; Sano and Reed 
2013). It is possible that a small fraction of the misfolded 
clarin 2 p.(Thr165Lys) could reach the plasma membrane 
via the unconventional secretory pathway, similar to that 
reported for clarin 1 p.(Asn48Lys) (p.(N48K)) (Gopal et al. 
2019). The unconventional secretory pathway is induced by 
the ER-associated misfolded or unfolded protein response 
(Kinseth et al. 2007; Schröder and Kaufman 2005). How-
ever, the mutant clarin 2 reaching the surface may be func-
tionally inactive. Second, evolutionarily conserved threo-
nine residues are also conserved protein phosphorylation 
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sites. Phosphorylation adds a negative charge to the side 
chain of the amino acid and it serves as an important post-
translational mechanism for regulation of protein function 
(Pearlman et al. 2011). Loss of threonine at position 165 
would potentially prevent functional activation of clarin 2. 
As our attempts to discriminate impact of the amino acid 
substitution in a human cell line yielded no conclusive 
results (KNA, unpublished data), additional experiments in 
an in vivo context are essential to test these hypotheses and 
unravel the true pathogenic mechanism associated with the 
p.(Thr165Lys) missense variant.
With respect to the aberrantly spliced CLRN2 transcripts, 
variants that disrupt splicing machinery signals are recognized 
as significant contributors to human genetic diseases (Xiong 
et al. 2015), with variants shown to impact accurate recogni-
tion and removal of intronic sequences from pre-mRNA (Fair-
brother et al. 2004). ESE sequences are cis-acting elements 
primarily recognized by the SR family proteins that function 
by recruiting core splicing machinery components to splice 
sites or by acting antagonistically against nearby silencing ele-
ments (Fairbrother et al. 2004; Graveley 2000; Kan and Green 
1999). ESEs are often associated with introns that contain 
weak splicing signals, but they can also reside in exons and 
impact the splicing process. Using mini-gene assays in human 
cell lines, we could show that the CLRN2 variant-induced 
aberrant splicing amounts to 10–15%, but its occurrence and 
rate in a biological context remains to be established. We, 
however, expect that the partial (only 3 out of 4 TM domains) 
and truncated (lack of C-terminal region) protein resulting 
from aberrant splicing due to CLRN2 c.494C > A variant is 
non-functional. Indeed, the integrity of all 4 TM domains 
seems to be necessary for a functional clarin tetraspan pro-
tein. This is supported by our data in Clrn2del629/del629 mice 
where transcripts lacking exon 2 do exist, but if translated 
would result in a predicted protein lacking the two central 
transmembrane domains. The severe hearing loss observed in 
these Clrn2del629/del629 mice clearly indicate that such partial 
clarin protein is insufficient to ensure normal hearing.
Repeated attempts to detect endogenous clarin 2 in the 
inner ear, under various conditions of fixation and antigen-
retrieval at different postnatal stages were unsuccessful. 
We therefore used in situ hybridization in zebrafish and in 
silico analyses in mouse to confirm predominant expression 
of Clrn2 in the sensory hair cells. To examine further the 
key role of clarin 2 in the inner ear, we generated zebrafish 
and mice lacking a functional protein. ABR measurements 
in Clrn2del629/del629 mice revealed an early-onset hearing 
loss with elevated hearing thresholds compared with their 
Clrn2+/+ littermate controls (mean click threshold 87 dB 
SPL ± 7 s.d. and 24 dB SPL ± 6 s.d., respectively). These 
data are consistent with early-onset hearing loss observed in 
another loss-of-function Clrn2 mutant (Clrn2clarinet), which 
harbors an early truncating nonsense variant (p.Trp4*) 
(Dunbar et al. 2019). However, comparison with the previ-
ously reported Clrn2clarinet P21 ABR data suggests that the 
extent of hearing loss in age-matched Clrn2del629 mice is 
more severe and less variable, which is most evident in the 
click ABR measures (80 ± 15 dB SPL and 87 ± 7 dB SPL, 
respectively). This difference could be due to strain effect, 
with the Clrn2clarinet mice being on a C57BL/6J background 
and the Clrn2del629 mice being on, the related but distinct, 
C57BL/6N (Simon et al. 2013). Interestingly, startle response 
measurements in clrn2 zebrafish crispants also reveal sig-
nificant reduction in sound-induced responses. This, together 
with the severe-to-profound hearing loss already exhibited 
at P21 and the reduced DPOAEs in both Clrn2del629/del629 
and in Clrn2clarinet/clarinet mice (Dunbar et al. 2019) points 
to gene defects likely affecting both inner hair cells (IHCs) 
and OHCs. This is further supported by scanning electron 
microscopy data showing loss of shortest row stereocilia in 
both the cochlear IHCs and OHCs. Phalloidin staining of 
clrn2 crispants also confirms hair bundle abnormalities in 
zebrafish. The loss of the mechanotransducing stereoclia, 
here the short stereocilia row in Clrn2del629/del629 and in 
Clrn2clarinet/clarinet mice is similar to that observed in hair cells 
defective for components of the mechanoelectrical transduc-
tion machinery. Electrophysiological recordings in OHCs of 
clarinet mice did indeed show that lack of clarin 2 causes sig-
nificant reduction in hair cell mechanoelectrical transduction 
activity (Dunbar et al. 2019). However, whether the loss of 
short row stereocilia is a downstream consequence of defec-
tive MET activity or due to yet unknown structural changes 
in the stereocilia remains to be established.
In conclusion, we demonstrate the c.494C > A variant 
affects exon 3 splicing efficiency. We showed, for the first 
time, that CLRN2 is a deafness-causing gene in humans. A 
variant causes hearing loss in humans, replicated by animal 
studies. Additional reports of families segregating CLRN2 
biallelic variants will be crucial to refine and dissect the 
clinical course and characteristics of hearing loss due to this 
gene. Together, our studies in zebrafish and mice establish 
that hearing loss is probably due to defective protein in the 
hair cells, where the presence of clarin 2 is essential for 
normal organization and maintenance of the mechanosensi-
tive hair bundles.
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